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Abstract
Objectives In this in-silico study, we investigate the clin-
ical utility of target-controlled infusion for antibiotic dos-
ing in an intensive care unit setting using vancomycin as a
model compound. We compared target-controlled infusion
and adaptive target-controlled infusion, which combines
target-controlled infusion with data from therapeutic drug
monitoring, with conventional (therapeutic drug monitor-
ing-based) vancomycin dosing strategies.
Methods A clinical trial simulation was conducted. This
simulation was based on a comprehensive database of
clinical records of intensive care unit patients and a sys-
tematic review of currently available population-pharma-
cokinetic models for vancomycin in intensive care unit
patients. Dosing strategies were compared in terms of the
probability of achieving efficacious concentrations as well
as the potential for inducing toxicity.
Results Adaptive target-controlled infusion outperforms
rule-based dosing guidelines for vancomycin. In the first
48 h of treatment, the probability of target attainment is
significantly higher for adaptive target-controlled infusion
than for the second-best method (Cristallini). Probability of
target attainments of 54 and 72% and 47 and 59% for both
methods after 24 and 48 h, respectively. Compared to the
Cristallini method, which is characterized by a probability
of attaining concentrations above 30 mg.L-1[65% in the
first few hours of treatment, adaptive target-controlled
infusion shows negligible time at risk and a probability of
attaining concentrations above 30 mg.L-1 not exceeding
25%. Finally, in contrast to the other methods, the per-
formance of target-controlled infusion is consistent across
subgroups within the population.
Conclusions Our study shows that adaptive target-con-
trolled infusion has the potential to become a practical tool
for patient-tailored antibiotic dosing in the intensive care
unit.
Key Points
In this proof-of-principle simulation study using
vancomycin as a model antibiotic for intensive care
unit patients, we showed for the first time that
adaptive target-controlled infusion could achieve a
higher degree of target attainment, achieve the target
faster, and minimize potential toxic overshoots
compared with conventional vancomycin dosing
guidelines.
Clinical pharmacologists involved in personalized
antibiotic dosing should know that the (adaptive)
target-controlled infusion technology has a
substantial track record and user base in anesthesia
and could be very useful for antibiotic dosing.
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s40262-018-0643-8) contains supple-
mentary material, which is available to authorized users.
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1 Introduction
Target-controlled infusion (TCI) is a technique of infusing
intravenous drugs to achieve a user-defined predicted
(‘target’) drug concentration in a specific body compart-
ment or tissue of interest [1]. Target-controlled infusion
systems are based on population-pharmacokinetic (PopPK)
[pharmacodynamics] models. For each individual patient,
the optimal infusion rate is calculated based on the
patient’s covariates (e.g. age, weight, estimated creatinine
clearance) and the user-defined target (plasma) concentra-
tion. For the open-loop TCI systems, the infusion scheme is
static, whereas for the closed-loop TCI systems, on-line
feedback from measured variables (e.g., processed elec-
troencephalography variables [2], blood pressure [3],
intermittently or continuously measured blood concentra-
tions [4], exhaled drug concentrations [5]) is used to adjust
the infusion rates continuously [6]. Target-controlled
infusion systems have been used in the field of anesthesia
for research and clinical purposes for over two decades
with an estimated 2.6 million patients in Europe receiving
one or more drugs by TCI per annum [7].
Compared to manually controlled infusions, theoreti-
cally TCI systems have the advantage of achieving the
target (plasma) concentration faster without a significant
overshoot of the target. This feature would be particularly
useful in the setting of antibiotic dosing where early and
appropriate therapy are likely associated with improved
patient survival [8–10]. Although PopPK models are
available for antibiotics, to our knowledge, no attempts
have been made to evaluate TCI systems in the field of
antimicrobial therapy.
Optimized dosing of antibiotics is usually based on
nomograms which define an initial dosing regimen based on
patient covariates. However, in the critically ill, these fixed
dosing regimens frequently result in a significant proportion
of patients not achieving the therapeutic target [11]. For
vancomycin, several studies demonstrated insufficient target
attainment in the first 3 days of therapy [12–15].
Therefore, in vulnerable patient populations these
nomograms are sometimes combined with therapeutic drug
monitoring (TDM). This TDM-guided treatment individu-
alization has been shown to increase clinical efficacy for
vancomycin [16] and reduce mortality rates during
aminoglycoside therapy [17].
Target-controlled infusion systems could replace these
nomogram-based dosing regimens, as it is known from
anesthesiology that TCI is generally more accurate com-
pared with manually controlled infusions [7]. At the same
time, closed-loop control of the TCI systems based on
TDM data could be accomplished through the use of
Bayesian statistics.
At present, Bayesian forecasting is used by different
TDM software such as DoseMe (DoseMe Pty Ltd.,
Brisbane, QLD, Australia), InsightRx (Insight Rx Inc.,
San Francisco, CA, USA), and MwPharm (Mediware a.s.,
Prague, Czech Republic). Some of these platforms require
trained personnel to handle the software and/or interpret
the output, thereby potentially hindering their widespread
use. Moreover, for the dosage adjustments, these systems
depend on humans, whose knowledge, judgment, and skill
set may not entirely align with the model-informed preci-
sion dosing paradigm [18, 19]. In contrast, TCI systems
provide direct communication with the infusion pump,
allowing fast and optimal individualization of the patient’s
infusion regimen.
In this simulation study, we investigated whether TCI
and/or a TDM-based closed-loop TCI system [named
‘adaptive TCI (aTCI)’ hereafter] would be useful for dos-
ing antibiotics in intensive care unit patients. We compare
the performance of this system to currently used (rule-
based) dosing guidelines. Vancomycin was chosen as a
model drug owing to (1) the availability in the literature of
different PopPK models, (2) the plethora of existing dosing
guidelines, (3) the frequent use of continuous infusion for
administering vancomycin [20], and (4) the widespread use
of TDM to monitor and adjust vancomycin dosing
regimens.
2 Materials and Methods
2.1 Sampling of Virtual Intensive Care Unit
Patients and Generation of Vancomycin
Pharmacokinetic Parameters
Patient records were randomly sampled from the MIMIC-
III database [21, 22]. This database comprises compre-
hensive clinical data of[10,000 patients from different
hospitals/intensive care units (ICUs). Based on the
covariates within these records (age, weight, height, sex,
serum creatinine), vancomycin pharmacokinetic (PK)
parameters were generated, and different PopPK models
were used.
These models were identified though a PubMed search
(until 27 September, 2017) using search terms: ‘‘van-
comycin AND population AND pharmacokinetics [Title/
Abstract]’’ OR ‘‘vancomycin AND pharmacokinetics AND
critically ill [Title/Abstract]’’. We restricted the search to
vancomycin models for adult patients only, thereby
excluding patients undergoing Continuous renal replace-
ment therapy, hemofiltration, and Extracorporeal mem-
brane oxygenation. In addition, models were retained only
if they were built on a dataset with a sample size[100
subjects and if the model’s performance was externally
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validated (i.e., prospective validation or validation using a
different cohort from the same trial).
The 10,000 sampled subjects were randomly allocated
to one of the PopPK models to generate vancomycin PK
parameters. The weight attributed to the PopPK models
during the random allocation was proportional to the
square root of the size of the model building datasets.
Vancomycin PK parameters were generated taking into
account the published covariate models as well as the
unknown (exponential) inter-individual variability around
the typical population parameters. Parameter uncertainty
was not taken into account.
2.2 Vancomycin Dosing Guidelines
A PubMed search (until 27 September, 2017) was con-
ducted using the search term: ‘‘vancomycin AND infusion
AND critically ill [Title/Abstract]’’. References of
retrieved articles were screened for additional references.
Only dosing guidelines developed for continuous infusion
were considered. We specifically looked for publications
that included recommendations for a loading dose and
defined rules to handle TDM data throughout therapy.
2.3 Target Controlled Infusion and Bayesian
Feedback
We choose the Thomson model [23] for implementation in
our (virtual) TCI system. This choice was based on the
Thomson model [23] being based on the biggest dataset to
date, the extensive validation of the model, and the broad
range of patient characteristics that were included. Prior to
the availability of TDM data, the TCI system uses the
covariate relationships contained in the Thomson model
[23] to calculate the optimal infusion regimen to approach
the target as fast as possible (these static infusion regimens
are hereafter referred to as ‘TCI’). The calculations are
based on the numeric approximation of the two-compart-
mental model as described by Shafer et al. [24]. To avoid
safety issues such as the ‘‘red man syndrome’’ [25] owing
to high infusion rates that are too high and in line with the
summary of product characteristics [26] for vancomycin,
the maximum infusion rate was set to 0.6 g.h-1.
After TDM data become available, the empirical Bayes
estimates (EBEs) for the PK parameters are found by
minimizing the objective function (Eq. 1). For our simu-
lation study, the EBEs were derived though NONMEM
(Version 7.3; Icon Development Solutions, Hanover, MD,
USA). However, in a TCI system, this is generally
accomplished through minimization of the objective
function with respect to the EBEs using Powell’s conjugate
direction method [27].
Objective function
¼
Pk
1 ðCobs  CpredÞ2
RUV
þ ðlogV1EBE  log TVV1Þ
2
V1
þ ðlogV2EBE  log TVV2Þ
2
V2
þ ðlogCLEBE  log TVCLÞ
2
CL
þ ðlogQ2EBE  log TVQ2Þ
2
Q2
: ð1Þ
In this equation, the sum of squared distances between
the measured vancomycin concentrations (Cobs) and the
predictions (Cpred) and the squared distances between the
typical PK parameters (TVV1, TVV2, TVCL, and TVQ2) and
the EBEs are weighted by their respective variance terms
(RUV, xV1, xV2, xCL, and xQ2). Both the typical PK
parameters and the associated variance terms were
calculated from the Thomson model. By minimizing this
function, the individual’s PK parameters (EBEs) that best
describe the observations are found. Subsequently, these
EBEs are used to re-calculate the optimal infusion regimen
(or the amount of time to stop the infusion) to attain the
user-defined target as fast as possible (this approach is
hereafter referred to as ‘aTCI’). A graphical representation
of this process is shown in Fig. S1 of the ESM.
2.4 Clinical Trial Simulation
An overview of the entire simulation workflow is shown in
Fig. S2 of the ESM. Virtual subjects were included in the
trial randomly between 00:00 and 23:59 on day 1 of the
study. Therapeutic drug monitoring samples were simu-
lated at 08:00 at days 2, 3, up to day 7. Therapeutic drug
monitoring data were used to individualize the vancomycin
dosing regimen only if the subjects had been taking van-
comycin for over 8 h. This results in the first TDM sample
being taken between 8 and 32 h after initiation of the
treatment.
The entire population of virtual subjects was used to
evaluate the different dosing methods. All conditions, time
of entry into the trial, and time of first TDM sample were
identical across the different dosing methods. For each
subject, the initial vancomycin dosing regimen was cal-
culated and the concentration–time profile generated up to
the time of the first TDM sample. The simulated TDM
sample was based on the PopPK model used to generate the
subject’s vancomycin PK parameters, taking into account
the model’s associated residual unexplained variability
(i.e., a ‘noisy’ TDM measurement was simulated instead of
the ‘true’ underlying concentration). Based on the TDM
sample, the dosing regimen was adjusted. Afterwards the
concentration–time profile up to the next TDM sample was
simulated, again using the PopPK model used to generate
TCI for Antibiotic Dosing 1437
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the subject’s vancomycin PK parameters. This process was
repeated up to 168 h after treatment initiation.
As we focused on the comparison between dosing reg-
imens to steer the ‘true’ individual concentrations towards
the target exposure, the subject’s ‘true’ individual con-
centration–time profile (i.e., without residual unexplained
variability) was used to calculate the performance metrics.
Based on these concentration–time profiles, time on target
(TOT) was calculated for each subject. It was expressed as
the percentage of the treatment period for which the sim-
ulated concentrations were within the target exposure. The
attainment of excessive vancomycin concentration was
similarly expressed as the proportion of the treatment
period for which the simulated vancomycin concentrations
were above 30 mg.L-1. For the remainder of the paper, we
refer to the latter as ‘time at risk’ (TAR).
The probabilities on the population level of attaining
target vancomycin concentrations (PTA) or attaining con-
centrations above 30 mg.L-1 (PTOX) were also derived.
For this, for each simulated time point, the proportion of
individuals with concentrations within target exposures or
above 30 mg.L-1 were calculated. Finally, we calculated
the time to steady-state target attainment (TTT) for all
simulated scenarios. This was defined as the time after
which simulated concentrations remained within the target
exposure (i.e., settling time for the dosing procedure).
All simulations were conducted in R (R Foundation for
Statistical Computing, Vienna, Austria) using packages
deSolve [28] and devtools [29].
3 Results
3.1 Virtual Subjects and Clinical Trial Simulation
Our PubMed search identified seven PopPK models
[23, 29–34] and four dosing guidelines [13, 35–37] that
fulfilled all our criteria. An overview of the PopPK models
and the dosing guidelines are given in Tables 1 and 2,
respectively. As a benchmark for the effectiveness of
TDM-based dosing vs. naı¨ve dosing, we included one
frequently referenced dosing guideline that does not
include rules for handling TDM data [38].
An overview of the characteristics of the virtual subjects
is shown in Table S1 of the ESM. The median time for the
first TDM sample was approximately 20 h. Vancomycin
PK parameters varied considerably between the different
groups.
Figure 1 shows the time course of the ‘true’ individual
vancomycin concentrations as well as the simulated TDM
samples and ensuing dosage adjustments for a representa-
tive subject of the Thomson group. Figures S3–8 of the
T
a
b
le
2
co
n
ti
n
u
ed
P
o
p
u
la
ti
o
n
L
o
ad
in
g
d
o
se
C
o
n
ti
n
u
o
u
s
in
fu
si
o
n
D
o
sa
g
e
ad
ju
st
m
en
t
T
ar
g
et
ex
p
o
su
re
?
C
ri
st
al
li
n
i
[3
6
]
A
d
u
lt
cr
it
ic
al
ly
il
l
p
at
ie
n
ts
;
in
te
rn
at
io
n
al
co
ll
ab
o
ra
ti
o
n
3
5
m
g
.k
g
-
1
o
v
er
4
h
[7
0
0
m
g
.h
-
1
]
eC
L
C
R
[
1
5
0
m
L
.m
in
-
1
:
4
5
m
g
.k
g
-
1
o
v
er
2
4
h
[1
5
0
m
g
.h
-
1
]
eC
L
C
R
[
1
2
0
m
L
.m
in
-
1
:
4
0
m
g
.k
g
-
1
o
v
er
2
4
h
[1
3
3
.3
m
g
.h
-
1
]
eC
L
C
R
[
8
0
m
L
.m
in
-
1
:
3
0
m
g
.k
g
-
1
o
v
er
2
4
h
[1
0
0
m
g
.h
-
1
]
eC
L
C
R
[
5
0
m
L
.m
in
-
1
:
2
5
m
g
.k
g
-
1
o
v
er
2
4
h
[8
3
.3
m
g
.h
-
1
]
eC
L
C
R
[
2
5
m
L
.m
in
-
1
:
1
4
m
g
.k
g
-
1
o
v
er
2
4
h
[4
6
.7
m
g
.h
-
1
]
eC
L
C
R
\
2
5
m
L
.m
in
-
1
:
7
m
g
.k
g
-
1
o
v
er
2
4
h
[2
3
.3
m
g
.h
-
1
]
C
p
[
3
0
m
g
.L
-
1
:
S
to
p
in
fu
si
o
n
fo
r
4
h
an
d
d
ec
re
as
e
in
fu
si
o
n
ra
te
w
it
h
2
5
%
C
p
\
2
0
m
g
.L
-
1
:
G
iv
e
5
0
0
-m
g
b
o
lu
s
an
d
in
cr
ea
se
in
fu
si
o
n
ra
te
w
it
h
2
5
%
C
p
\
1
5
m
g
.L
-
1
:
G
iv
e
1
0
0
0
-m
g
b
o
lu
s
an
d
in
cr
ea
se
in
fu
si
o
n
ra
te
w
it
h
2
5
%
C
ss
:
2
0
–
3
0
m
g
.L
-
1
N
u
m
b
er
s
b
et
w
ee
n
sq
u
ar
e
b
ra
ck
et
s
in
d
ic
at
e
th
e
in
fu
si
o
n
ra
te
s
fo
r
a
ty
p
ic
al
8
0
-k
g
p
at
ie
n
t
w
it
h
an
eC
L
C
R
o
f
6
0
m
L
.m
in
-
1
u
n
le
ss
st
at
ed
o
th
er
w
is
e
C
ss
st
ea
d
y
-s
ta
te
p
la
sm
a
co
n
ce
n
tr
at
io
n
,
C
p
m
ea
su
re
d
v
an
co
m
y
ci
n
co
n
ce
n
tr
at
io
n
in
p
la
sm
a,
eC
L
C
R
es
ti
m
at
ed
cr
ea
ti
n
in
e
cl
ea
ra
n
ce
,
IC
U
in
te
n
si
v
e
ca
re
u
n
it
a
D
o
se
s
ro
u
n
d
ed
o
ff
to
m
u
lt
ip
le
s
o
f
1
2
5
m
g
1440 P. Colin et al.
ESM show the simulations for a subject from the other
groups.
3.2 Target Attainment, Time to Steady-State Target
Attainment, and Time at Risk
Figure 2 shows the distribution of TOT and TAR for the
different dosing methods. A naı¨ve application of TCI that
does not use TDM-based Bayesian feedback (TCI) was
also evaluated. Time on target is highest for aTCI with an
inter-quartile range from 53 to 91%. In comparison, TOT
for the other methods is lower. The methods that do not use
TDM to individualize treatment show a bimodal distribu-
tion with a significant proportion of the population having
very low TOT (e.g., 50% of subjects in the Pea and TCI
group have a TOT below 25 and 22%, respectively). The
median TAR is markedly higher for the Ampe (23%) and
Cristallini (5.5%) method compared with aTCI (0.0%). The
method of Pea has the lowest TAR owing to the fact that a
lower Css is targeted, i.e., 20 mg.L
-1 instead of 25 mg.L-1.
The methods are compared in more detail in Table 3.
Based on all data, aTCI has the highest median TOT
(77.4%). The Cristallini method, which ranks second,
performs less well (71.6%). At the same time, the median
TAR and median TTT is lowest in the aTCI group. The
proportion of virtual subjects not attaining the target after
7 days of treatment ranges between[60% for the non-in-
dividualized methods and 16% for the Cristallini method.
Fig. 1 Simulated ‘true’ individual concentrations and therapeutic
drug monitoring samples for a representative individual from the
Thomson group. The horizontal red lines show the boundaries for the
targeted vancomycin exposure according to the different dosing
methods. aTCI adaptive target-controlled infusion, TCI target-con-
trolled infusion
TCI for Antibiotic Dosing 1441
At 25%, aTCI performs similar to the methods of Saugel
(22%), Ampe (25%), and Ocampos-Martinez (24%).
As our aTCI system is based on the Thomson model and
this model was also used to generate vancomycin PK
parameters for 20% of the virtual subjects, we wanted to
evaluate whether this confounded our results. Therefore, a
subgroup analysis was performed across the different
PopPK models. As seen from Table S2 of the ESM, aTCI
has the highest median TOT, the lowest median TAR, and
the lowest TTT in respectively five, six, and five groups out
of seven.
Finally, we wanted to evaluate the performance of the
methods across different subgroups within the simulated
population. The results were stratified with respect to body
weight or estimated renal function. In general, the perfor-
mance of aTCI is similar across subgroups. Moreover, for
each of the subgroups, aTCI has the highest median TOT.
For the other methods, TOT decreased and TTT increased
significantly in subject with low body weight (\58 kg) and
subjects with low renal function (\60 mL.min-1).
Subjects with high renal function ([120 mL.min-1) and
high body weight ([110 kg) appear to be at risk for
excessive vancomycin concentrations when dosed using
the Cristallini method (9.7%) and the Ampe method (24%).
3.3 Probability of Target Attainment
and Probability of Attainment of Excessive
Vancomycin Concentrations
within the Population
Figures 3 and 4 show the PTA and the probability of
attainment of excessive vancomycin concentrations
(PTOX) within the population as a function of time. In the
first few hours, TCI, aTCI, and the method of Pea attain
PTAs above 50%. However, for both TCI and the method
of Pea, PTAs worsen and beyond 48 h their PTAs are
lowest. The PTAs for the other methods first decrease
(slightly) before starting to increase owing to the effect of
TDM-based treatment individualization. The increase in
PTA is fastest in the aTCI group with the maximum PTA
Fig. 2 Violin plot showing the
distribution of time on target
and time at risk for the different
simulated dosing guidelines. For
clarity, individual estimates
(circles) are shown for only
2000 virtual subjects out of
10,000. The 25th, 50th, and 75th
percentiles of the empirical
cumulative distribution function
are shown with vertical lines in
the violin plots. These were
estimated on all the data. The
shape of the violin shows the
empirical cumulative density
curve. Time on target and time
at risk are calculated as the
proportion of the treatment
when vancomycin
concentrations are within the
target exposure or above
30 mg.L-1. Target vancomycin
concentrations are between 20
and 30 mg.L-1 for all methods
except Pea where
concentrations between 15 and
25 mg.L-1 are targeted. aTCI
adaptive target-controlled
infusion, TCI target-controlled
infusion
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of 77% being reached by 51 h. The method of Cristallini
achieves a maximum PTA of approximately 84%, but
requires 109 h to do so. The methods of Ocampos-Marti-
nez, Saugel, and Ampe approach maximum PTAs of 78,
78, and 78% by 123, 125, and 124 h, respectively.
Looking at the possibility of attaining excessive van-
comycin concentrations (i.e., Cp[30 mg.L
-1), the method
of Cristallini stands out with a PTOX[65% in the first few
hours. During this period, the median predicted van-
comycin concentration is 66 mg.mL-1. This PTOX pre-
vails up to approximately 20 h. The second highest ranking
method was Ampe with a PTOX and associated median
vancomycin concentration of 38% and 33 mg.L-1,
respectively. After 24 h, PTOX is similar across methods
ranging between 15 and 28%. The only exception is the
method of Pea (6%), which targets a lower Css compared
with the other methods.
4 Discussion
Through a clinical trial simulation, we showed that aTCI
outperforms rule-based dosing guidelines for vancomycin.
With a PTA of 70% reached within 42 h, aTCI is much
faster than the second best method (Cristallini), which
requires 70 h to achieve a PTA of 70%. Consequently, in
the first 48 h of treatment, PTAs are significantly higher for
aTCI than for the Cristallini method (PTAs of 54 and 72%
and 47 and 59% for both methods after 24 and 48 h,
respectively). Compared with the Cristallini method, which
is characterized by a PTOX[65% in the first few hours of
treatment, aTCI shows negligible time at risk and a PTOX
not exceeding 25%. Finally, in contrast to the other
methods, the performance of aTCI is consistent across
subgroups within the population.
Our approach of combining physiological data from an
ICU database with different published PopPK models
resulted in the generation of a very heterogeneous virtual
population. However, looking at the publications describ-
ing the dosing guidelines, it appears that our simulation
reproduces some features of those clinical trials. Ocampos-
Martinez et al. [13] showed that the PTA is approximately
40, 50, and 70% 1, 2, and 3 days after treatment initiation.
Our simulations showed a PTA of 41, 55, and 64% after 1,
2, and 3 days of treatment. Furthermore, Cristallini et al.
[36] showed that 86, 28, and 17% of patients attained
excessive vancomycin concentrations after 4, 12, and 24 h,
respectively. This is also in good agreement with the
simulated dynamics in our simulation where 68, 32, and
20% of patients attained excessive vancomycin
Table 3 Estimates of the performance for the best three vancomycin dosing guidelines (sorted by decreasing target attainment)
Subgroup Method Time on target
(%)
Time at risk
(%)
Time to target
(h)
Proportion of subjects outside target at
168 h (%)
All data aTCI 77.4 0.00 70.4 24.8
Cristallini 71.6 5.54 88.1 15.7
Saugel 67.3 0.18 91.3 22.1
Only data simulated with Thomson
model
aTCI 91.5 0.00 26.3 12.9
Cristallini 77.3 6.99 76.7 12.6
Saugel 74.4 0.00 83.7 17.4
Low body weight (\58 kg) aTCI 79.3 0.00 55.2 23.5
Cristallini 64.8 4.40 105 19.1
Saugel 62.1 1.96 108 25.6
High body weight ([110 kg) aTCI 76.3 0.00 49.8 25.7
Cristallini 72.1 9.73 75.6 15.3
Ocampos-
Martinez
67.6 0.00 85.8 21.3
Low renal function
(eCLCR\60 mL.min
-1)
aTCI 73.9 0.00 59.7 27.6
Cristallini 69.5 9.29 92.0 17.4
Saugel 65.8 14.8 97.2 27.1
High renal function
(eCLCR[120 mL.min
-1)
aTCI 79.7 0.00 97.2 20.5
Ampe 72.7 23.8 69.2 15.7
Cristallini 72.0 3.81 89.1 15.0
All performance metrics define the median in the subgroup
aTCI adaptive target-controlled infusion
TCI for Antibiotic Dosing 1443
concentrations 4, 12, and 24 h after treatment initiation.
Overall, these agreements between the simulated and
reported performance characteristics inspire confidence in
the conclusions drawn from our simulation study.
There are limitations to our proposed methodology.
First, in our simulations, we assumed that intra-individual
variability is negligible. From the literature, it seems that
indeed for vancomycin intra-individual variability has little
clinical relevance [39]. Nevertheless, for other antibiotics it
might be necessary to consider intra-individual variability
as it is not entirely clear whether this would equally impact
the performance of the different dosing methods. Second,
the performance metrics used to compare the methods were
based on the interpretation of the authors of the dosing
guidelines [13, 36, 37] and align with recent work by
Zasowski et al. [40] However, these might be judged too
high or too low by others (see Filippone et al. [41] for a
detailed discussion of vancomycin-induced
nephrotoxicity).
The lower steady-state PTA for aTCI is indicative of a
mismatch between the clearance model in the TCI system
and the clearance models that were used for the trial sim-
ulation. By combining seven PopPK models for our sim-
ulations we are over-emphasizing this mismatch. This led
to a very conservative yet robust estimate of the perfor-
mance characteristics of the aTCI system. In our opinion,
this inspires confidence with respect to the generalizability
of our conclusions. Furthermore, in clinical practice, it is
likely that when a patient’s TDM samples are consequently
off-target the plasma target is changed to overcome the
imprecision of the TCI system. As such, we feel that in
clinical practice, steady-state PTA will likely be higher
than what is seen from our simulations.
At present, there is no consensus on the ‘best’ van-
comycin model and associated covariates. A pooled anal-
ysis of the data could alleviate some of this uncertainty. In
line with what was done for propofol by Eleveld et al. [42]
this pooled analysis could form the basis for a ‘‘general
purpose vancomycin PK model’’. Such a model would
dramatically increase the performance of an aTCI system.
Indeed, as seen from Table 3, when aTCI is based on a
model that adequately describes the PKs within the popu-
lation (as does our aTCI system for the Thomson group),
TOT becomes very high with minimal time to steady-state
target attainment and a minimal proportion of subjects not
attaining the target.
Adapted TCI uses Bayesian forecasting to individualize
dosing regimens based on TDM data. Approaches using
Fig. 3 Probability of target
attainment vs. time for the
different simulated dosing
guidelines. aTCI adaptive
target-controlled infusion, TCI
target-controlled infusion
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more traditional PK modeling software have been descri-
bed by others in the field of antibiotic [43, 44], antifungal
[45, 46] and antiviral therapy [47]. Although aTCI and
more traditional TDM software use a similar theoretical
framework for dosage individualisation, aTCI has some
advantages. First, as shown in this study, target attainment
is fast with minimum overshoot of the target concentration.
Second, in contrast to the other methods, dosage adjust-
ments with aTCI are continuous and are not limited to
discrete changes in infusion rates. We hypothesize that this
means dosage individualization would be more precise
with aTCI as compared to other methods. Evidently, this
remains to be confirmed in future prospective evaluations.
Finally, aTCI has the practicable advantage of flexibility,
i.e., it facilitates the use of a patient-tailored target.
It is noteworthy to appreciate that TCI has been around
for decades and is currently used in operating rooms and
ICUs across the world (except for USA). In our opinion,
this poses the opportunity to introduce model-informed
personalized dosing of antibiotics via a dosing device that
is already somewhat familiar to most practitioners. We
believe that this familiarity could facilitate the widespread
implementation of model-informed precision dosing.
5 Conclusions
Through our clinical trial simulation, we showed that the
performance of aTCI is superior compared to currently
used dosing guidelines. In an era where model-informed
precision dosing is gaining popularity and treatment indi-
vidualization is increasingly used in conjunction with
TDM, we feel that aTCI would be a useful addition to the
already available set of tools for patient-tailored antibiotic
dosing.
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